Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:OCSNASDAQ:QURENASDAQ:SNDXNASDAQ:TNXP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeOCSOculis$19.89+4.6%$17.89$10.79▼$23.08$868.44M0.2743,949 shs66,080 shsQUREuniQure$15.50+2.2%$12.50$3.73▼$19.18$849.03M0.11.90 million shs1.12 million shsSNDXSyndax Pharmaceuticals$9.93+0.8%$11.68$8.58▼$25.07$847.56M0.821.78 million shs2.81 million shsTNXPTonix Pharmaceuticals$36.99+27.9%$20.78$6.76▼$574.08$270.95M1.63874,663 shs3.33 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceOCSOculis+4.63%+13.01%+17.00%-3.26%+67.85%QUREuniQure+2.24%+1.24%+9.31%+32.82%+225.63%SNDXSyndax Pharmaceuticals+0.81%-6.05%-25.51%-36.22%-51.04%TNXPTonix Pharmaceuticals+27.86%+23.71%+107.58%+338.79%-93.41%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationOCSOculis2.6104 of 5 stars3.55.00.00.02.70.00.6QUREuniQure3.2839 of 5 stars4.52.00.00.02.82.50.6SNDXSyndax Pharmaceuticals3.8128 of 5 stars4.51.00.04.43.00.00.0TNXPTonix Pharmaceuticals3.6146 of 5 stars3.54.00.00.03.03.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceOCSOculis 3.00Buy$31.5058.37% UpsideQUREuniQure 2.91Moderate Buy$37.82143.99% UpsideSNDXSyndax Pharmaceuticals 2.91Moderate Buy$35.91261.62% UpsideTNXPTonix Pharmaceuticals 3.00Buy$585.001,481.51% UpsideCurrent Analyst Ratings BreakdownLatest TNXP, OCS, QURE, and SNDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025QUREuniQureCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/12/2025QUREuniQureGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.005/12/2025QUREuniQureChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.005/9/2025OCSOculisChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$28.00 ➝ $33.005/6/2025QUREuniQureChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.005/6/2025SNDXSyndax PharmaceuticalsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$16.00 ➝ $17.005/6/2025SNDXSyndax PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.004/21/2025QUREuniQureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $70.004/17/2025OCSOculisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$29.00 ➝ $32.004/17/2025OCSOculisChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.004/1/2025QUREuniQureChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$27.00 ➝ $38.00(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookOCSOculis$980K886.16N/AN/A$2.87 per share6.93QUREuniQure$20.20M42.03N/AN/A$4.34 per share3.57SNDXSyndax Pharmaceuticals$43.72M19.54N/AN/A$6.53 per share1.52TNXPTonix Pharmaceuticals$10.04M26.98N/AN/A$5,751.80 per share0.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateOCSOculis-$98.92M-$2.64N/AN/AN/A-8,043.28%-71.31%-56.85%N/AQUREuniQure-$308.48M-$4.39N/AN/AN/A-837.80%-188.82%-32.17%8/7/2025 (Estimated)SNDXSyndax Pharmaceuticals-$209.36M-$3.86N/AN/AN/AN/A-64.34%-57.72%8/7/2025 (Estimated)TNXPTonix Pharmaceuticals-$116.66M-$1,963.61N/AN/AN/A-1,197.86%-163.95%-118.88%8/15/2025 (Estimated)Latest TNXP, OCS, QURE, and SNDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025TNXPTonix Pharmaceuticals-$3.23-$2.84+$0.39-$2.84$2.55 million$2.43 million5/9/2025Q1 2025QUREuniQure-$1.07-$0.82+$0.25-$0.82$5.93 million$1.57 million5/8/2025Q1 2025OCSOculis-$0.51-$0.77-$0.26-$0.77$0.22 million$0.32 million5/5/2025Q1 2025SNDXSyndax Pharmaceuticals-$1.04-$0.98+$0.06-$0.98$15.88 million$20.04 million3/18/2025Q4 2024TNXPTonix Pharmaceuticals-$6.23-$9.77-$3.54-$9.77$3.20 million$2.58 million3/11/2025Q4 2024OCSOculis-$0.48-$0.76-$0.28-$0.76$0.21 millionN/A3/3/2025Q4 2024SNDXSyndax Pharmaceuticals-$0.31-$1.10-$0.79-$1.10$86.32 million$7.68 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthOCSOculisN/AN/AN/AN/AN/AQUREuniQureN/AN/AN/AN/AN/ASNDXSyndax PharmaceuticalsN/AN/AN/AN/AN/ATNXPTonix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioOCSOculis0.014.024.02QUREuniQure0.926.516.51SNDXSyndax PharmaceuticalsN/A6.996.99TNXPTonix Pharmaceuticals0.073.332.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipOCSOculis22.30%QUREuniQure78.83%SNDXSyndax PharmaceuticalsN/ATNXPTonix Pharmaceuticals82.26%Insider OwnershipCompanyInsider OwnershipOCSOculisN/AQUREuniQure4.74%SNDXSyndax Pharmaceuticals4.10%TNXPTonix Pharmaceuticals0.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableOCSOculis243.66 millionN/ANot OptionableQUREuniQure50054.78 million46.43 millionOptionableSNDXSyndax Pharmaceuticals11086.05 million81.86 millionOptionableTNXPTonix Pharmaceuticals507.33 million1.87 millionNot OptionableTNXP, OCS, QURE, and SNDX HeadlinesRecent News About These CompaniesTonix Pharmaceuticals (NASDAQ:TNXP) Shares Up 9% - Here's WhyMay 27 at 2:34 PM | marketbeat.comTonix Pharmaceuticals (NASDAQ:TNXP) Trading 2.8% Higher - Still a Buy?May 25 at 4:02 PM | marketbeat.comPoint72 Asset Management L.P. Makes New $526,000 Investment in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)May 25 at 4:04 AM | marketbeat.comTonix Pharmaceuticals (NASDAQ:TNXP) Upgraded at Wall Street ZenMay 24, 2025 | marketbeat.comTonix Pharmaceuticals CEO Seth Lederman Participates in A.G.P. Annual Healthcare Company ShowcaseMay 22, 2025 | quiverquant.comTonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company ShowcaseMay 22, 2025 | globenewswire.comTonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress ReactionMay 21, 2025 | globenewswire.comTonix Pharmaceuticals (NASDAQ:TNXP) Trading Up 18.8% on Insider Buying ActivityMay 18, 2025 | americanbankingnews.comTonix Pharmaceuticals (NASDAQ:TNXP) Shares Pass Above 200-Day Moving Average - Here's WhyMay 17, 2025 | marketbeat.comTonix Pharmaceuticals (TNXP) Stock Surges Following Insider Buying And Q1 ResultsMay 16, 2025 | benzinga.comInsider Buying: Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) CEO Purchases 4,000 Shares of StockMay 16, 2025 | insidertrades.comWhy Tonix Pharmaceuticals Holding Corp.’s (TNXP) Stock Is Up 5.05%May 15, 2025 | aaii.comTonix Pharma Stock Soars After Roping In Former Celgene Corp Executive Joseph Hand: Retail Gets More PositiveMay 15, 2025 | msn.comTonix Pharmaceuticals (NASDAQ:TNXP) Releases Earnings Results, Beats Expectations By $0.39 EPSMay 14, 2025 | marketbeat.comTonix Pharmaceuticals Announces Appointment of Joseph Hand, Esq. ...May 14, 2025 | gurufocus.comTonix Pharmaceuticals (TNXP) Appoints New General Counsel and EVP of Operations | TNXP Stock NewsMay 14, 2025 | gurufocus.comTonix Pharma Appoints New General Counsel and EVPMay 14, 2025 | tipranks.comTonix Pharmaceuticals Announces Appointment of Joseph Hand, Esq., as General Counsel and Executive Vice President of OperationsMay 14, 2025 | globenewswire.comTonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational HighlightsMay 13, 2025 | finanznachrichten.deTonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights | ...May 12, 2025 | gurufocus.comTonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational HighlightsMay 12, 2025 | gurufocus.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTNXP, OCS, QURE, and SNDX Company DescriptionsOculis NASDAQ:OCS$19.89 +0.88 (+4.63%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$19.86 -0.03 (-0.13%) As of 05/27/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.uniQure NASDAQ:QURE$15.50 +0.34 (+2.24%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$15.46 -0.04 (-0.29%) As of 05/27/2025 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.Syndax Pharmaceuticals NASDAQ:SNDX$9.93 +0.08 (+0.81%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$10.15 +0.22 (+2.23%) As of 05/27/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Tonix Pharmaceuticals NASDAQ:TNXP$36.99 +8.06 (+27.86%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$37.12 +0.13 (+0.36%) As of 05/27/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings Palantir Scores First $1 Billion Contract; Is It Priced In? Tesla: Why Analysts Think It Could Jump Another 47% Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook 3 Dividend Stocks to Get You Through Tariff Volatility Apple Sinks After New 25% Tariff Announcement—What's The Bottom? MarketBeat Week in Review – 05/19 - 05/23 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
